Eyepoint Pharmaceuticals (NASDAQ:EYPT) received a $3.00 price target from stock analysts at HC Wainwright in a research report issued to clients and investors on Thursday, August 2nd. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 36.36% from the stock’s previous close.
EYPT has been the subject of a number of other reports. ValuEngine raised Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Zacks Investment Research raised Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research report on Tuesday, April 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $4.90.
Eyepoint Pharmaceuticals traded up $0.05, reaching $2.20, on Thursday, according to MarketBeat.com. 246,551 shares of the stock traded hands, compared to its average volume of 269,394. The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of 1.57. The firm has a market cap of $116.16 million, a PE ratio of -4.23 and a beta of 1.01. Eyepoint Pharmaceuticals has a 12 month low of $0.93 and a 12 month high of $2.88.
A number of institutional investors have recently bought and sold shares of EYPT. FineMark National Bank & Trust purchased a new stake in Eyepoint Pharmaceuticals during the 2nd quarter valued at about $118,000. Creative Planning purchased a new stake in shares of Eyepoint Pharmaceuticals in the second quarter worth about $162,000. Essex Investment Management Co. LLC purchased a new stake in shares of Eyepoint Pharmaceuticals in the second quarter worth about $170,000. Finally, BlackRock Inc. purchased a new stake in shares of Eyepoint Pharmaceuticals in the second quarter worth about $304,000. Institutional investors and hedge funds own 24.14% of the company’s stock.
About Eyepoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis.
Featured Article: Outstanding Shares and The Effect on Share Price
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.